<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02639858</url>
  </required_header>
  <id_info>
    <org_study_id>DOCH&amp;N201</org_study_id>
    <nct_id>NCT02639858</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC</brief_title>
  <official_title>A Phase II Study to Evaluate the Efficacy and Safety of Docetaxel-PM in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samyang Biopharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samyang Biopharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II study to evaluate the efficacy and safety of Docetaxel-PM in recurrent or
      metastatic head and neck squamous cell carcinoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate as assessed by RECIST v1.1</measure>
    <time_frame>2 years</time_frame>
    <description>Response is confirmed at least 4 weeks later. Assessment: every 6 weeks (treatment period), every 2 months (follow-up period)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment: every 2 months (follow-up period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>2 years</time_frame>
    <description>DCR is defined as the percentage of patients who have achieved complete response, partial response and stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Assessment: every 2 months (follow-up period)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of hypersensitivity reaction to Docetaxel-PM</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Docetaxel-PM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel-PM 75mg/m2 IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel-PM</intervention_name>
    <description>Docetaxel PM 75mg/m2 IV infusion</description>
    <arm_group_label>Docetaxel-PM</arm_group_label>
    <other_name>Nanoxel M</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who were histologically or cytologically diagnosed as having oral cavity,
             oropharynx, hypopharynx, or larynx squamous cell carcinoma with recurrent and
             metastatic evidence and who cannot be treated by salvage surgery or radiotherapy

          2. Time of disease progression, regardless of whether that treatment or after
             platinum-based therapy

             ①Patients who have disease progression after concurrent chemoradiotherapy of curative
             purpose (including induction chemotherapy) including a platinum-based (cisplatin or
             carboplatin) chemotherapy

             ② Patients who have disease progression after primary or secondary treatment of
             palliative purpose including a platinum-based (cisplatin or carboplatin) chemotherapy

          3. Patients who aged 20 years or older and under 79 years old

          4. Patients whose Eastern Cooperative Oncology Group (ECOG) performance scores are 0-2

          5. Patients who have one measurable lesion at least by RECIST criteria 1.1

          6. Patients who show adequate function of organ:

               -  bone marrow: Absolute Neutrophil count (ANC) ≥ 1,500/μL, Platelet count ≥
                  100,000/μ, Hb≥ 9.0 g/dl (allowed blood transfusion)

               -  Liver: ① with no evidence of liver metastasis; Total bilirubin ≤ 1.5mg/dl,
                  alkaline phosphatase (ALP), aspartate transaminase (AST), alanine transaminase
                  (ALT) ≤ 2.0 X upper limit of normal (ULN)

                  ② with liver metastasis; bilirubin ≤ 3.0 X ULN, aspartate transaminase (AST),
                  alanine transaminase (ALT) ≤ 5.0 X ULN

               -  Kidney: creatinine ≤ 1.5 X ULN

          7. Patients who have signed written consent forms prior to participation in the clinical
             trial

        Exclusion Criteria:

          1. Patients who have Primary tumor of nasopharynx

          2. Patients who have received treatment prior regimen of three or more drugs

          3. Patients who have Primary malignant tumors of other sites (except if; early cervical
             cancer, skin basal cell cancer received appropriate treatment, Malignant tumor without
             recurrent state treated five years previously)

          4. Previous radiotherapy is allowed, patients who should be completed radiotherapy before
             4 weeks prior to the initial administration of the investigational product

          5. Patients who have received a major surgery within 4 weeks prior to the initial
             administration of the investigational product or patients who does not recover after
             major surgery

          6. Patients who have severe diseases or medical condition as follows

               -  Congestive heart failure(NYHA class III or IV)

               -  Unstable angina, cardiac infarction within 6 months

               -  Second-degree atrioventricular (AV) block or more, clinically cardiac arrhythmia
                  that needs drug therapy

               -  Uncontrollable Hypertension

               -  Hepatic cirrhosis (≥ Child class B)

               -  Interstitial lung disease

               -  Mental disorder not to comply with the protocol

               -  Uncontrolled diabetes

               -  Uncontrolled ascites or pulmonary edema

               -  Active infection

          7. Pregnant or lactating women

          8. Patients considered inappropriate to participating the study by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samyang Biopharmaceuticals</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miryung Jin</last_name>
      <phone>+82-2-740-7289</phone>
      <email>miryung.jin@samyang.com</email>
    </contact>
    <investigator>
      <last_name>Sung Bae Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2015</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

